AstraZeneca Announced Saturday, IMFINZI Plus Tarlatamab-dlle Cuts Death Risk 58% Versus IMFINZI Alone In First-Line Extensive-Stage Small Cell Lung Cancer, Median OS 21.1 Versus 12.7 Months, In DeLLphi-305 Phase III
Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trialResults reinforce IMFINZI as the backbone immunotherapy
Share
Why It Matters
AstraZeneca's new cancer medicine combination helped patients live much longer. When a medicine shows it helps sick people more, that's usually good news for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.